Huang H, Ding W, Su Z, Zhang W
Department of Pediatric Thoracocardiac Surgery, Xinhua Hospital, Shanghai Second Medical University, China.
J Thorac Cardiovasc Surg. 1993 Jul;106(1):11-8.
The deficiency of platelet function is the main defect of the hemostatic mechanism during cardiopulmonary bypass, which greatly exacerbates the postoperative bleeding complications. In this study, we assessed, from basic and clinical perspectives, the mechanism of relieving platelet damage by means of aprotinin. In vitro research confirmed that the addition of urokinase (40 U/ml) to platelet-rich plasma and the addition of plasmin (0.3 U/ml) to washed platelets made ristocetin-induced agglutination decline to 31.6% and 38.5% of control values, respectively. The extent of decline was positively correlated with the concentration of urokinase and plasmin. In addition, the platelet membrane glycoprotein Ib decreased to 76.4% of control value. With the addition of urokinase or plasmin to aprotinin-pretreated platelet-rich plasma or washed platelets, the changes in agglutination are not statistically significant and the decrement in glycoprotein Ib is much less marked. Further in vivo research revealed that cardiopulmonary bypass caused a decrease in plasma alpha 2-antiplasmin, indicating the fibrinolytic system activation. Meanwhile, ristocetin-induced agglutination decreased to 39.6% and platelet glycoprotein Ib decreased to 50% of preoperative values. However, with the administration of aprotinin, plasma alpha 2-antiplasmin during cardiopulmonary bypass did not change; platelet agglutination was improved, platelet glycoprotein Ib was preserved, and this consequently resulted in 46% lower blood loss after the operation. The results showed that fibrinolysis impaired platelet function, and this effect may be associated with the hydrolysis of glycoprotein Ib. Fibrinolytic activation occurred during cardiopulmonary bypass and contributed to postoperative platelet dysfunction to a great extent. Aprotinin may inhibit fibrinolysis during cardiopulmonary bypass and thus relieve the platelet damage and improve the postoperative hemostatic mechanism.
血小板功能缺陷是体外循环期间止血机制的主要缺陷,这极大地加剧了术后出血并发症。在本研究中,我们从基础和临床角度评估了抑肽酶减轻血小板损伤的机制。体外研究证实,向富含血小板血浆中添加尿激酶(40 U/ml)以及向洗涤后的血小板中添加纤溶酶(0.3 U/ml),分别使瑞斯托霉素诱导的凝集下降至对照值的31.6%和38.5%。下降程度与尿激酶和纤溶酶的浓度呈正相关。此外,血小板膜糖蛋白Ib降至对照值的76.4%。在经抑肽酶预处理的富含血小板血浆或洗涤后的血小板中添加尿激酶或纤溶酶,凝集的变化无统计学意义,糖蛋白Ib的减少也不明显。进一步的体内研究表明,体外循环导致血浆α2-抗纤溶酶减少,表明纤溶系统激活。同时,瑞斯托霉素诱导的凝集降至术前值的39.6%,血小板糖蛋白Ib降至术前值的50%。然而,使用抑肽酶后,体外循环期间血浆α2-抗纤溶酶未发生变化;血小板凝集得到改善,血小板糖蛋白Ib得以保留,这从而使术后失血量减少了46%。结果表明,纤溶作用损害了血小板功能,且这种作用可能与糖蛋白Ib的水解有关。体外循环期间发生纤溶激活,在很大程度上导致了术后血小板功能障碍。抑肽酶可能在体外循环期间抑制纤溶,从而减轻血小板损伤并改善术后止血机制。